OOIR: Observatory of International Research

Papers

(The H4-Index of Gut is 89. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19	809
Mucus barrier, mucins and gut microbiota: the expected slimy partners?	725
Gut microbiome and health: mechanistic insights	711
Gut microbiota-derived metabolites as central regulators in metabolic disorders	527
Interaction between drugs and the gut microbiome	449
Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report	415
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites	392
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN	351
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort	302
Global burden of oesophageal and gastric cancer by histology and subsite in 2018	297
Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome	285
Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health	278
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases	252
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome	251
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus	241
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals	238
Effect of IBD medications on COVID-19 outcomes: results from an international registry	221
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome	214
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD	201
Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19	197
The role of gut microbiota in cancer treatment: friend or foe?	194
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis	189
Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis	188
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) imm	183
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study	176

Calprotectin: from biomarker to biological function	172
Guidelines on the management of ascites in cirrhosis	171
Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology	169
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting	166
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19	165
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial	165
Helicobacter pyloriresistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community	161
Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing	155
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores	152
Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching	151
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort	151
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis	150
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups	146
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning	144
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab	144
European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients	141
Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation	134
Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide	131
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer	128
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease	128
Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn	127
Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study	126
Diet quality and risk and severity of COVID-19: a prospective cohort study	126
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies	125
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges	123
Six-month follow-up of gut microbiota richness in patients with COVID-19	122
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial	121
COVID-19 in an international European liver transplant recipient cohort	114
Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade	113
A faecal microbiota signature with high specificity for pancreatic cancer	112
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis	112
Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis	111
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic	109
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?	107
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives	107
Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer	106
Artificial intelligence and colonoscopy experience: lessons from two randomised trials	105
Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma	103
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19	103
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19	103
Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study	101
Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis	100
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort	100
Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16	100
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma	100
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series	99
Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies	99
Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure	99
Recent advances in clinical practice: epidemiology of autoimmune liver diseases	97
Lactobacillus gallinarummodulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis	97

Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning	95
Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic func	93
Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury	93
British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults	93
Disrupted spermatogenesis in a metabolic syndrome model: the role of vitamin A metabolism in the gut–testis axis	93
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women	93
Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice	92
Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites	92
Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis	90
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies	90
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	90
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population	90
Current therapies and new developments in NASH	89
Novel therapeutic targets for cholestatic and fatty liver disease	89
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification	89
Angiogenin maintains gut microbe homeostasis by balancing α-Proteobacteria and Lachnospiraceae	89